Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review

AIMS: There is a controversy as to the relative efficacy of (177)Lu prostate specific membrane antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of our systematic review was to elucidate whether (177)L...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Eur J Nucl Med Mol Imaging
Autori principali: von Eyben, Finn Edler, Roviello, Giandomenico, Kiljunen, Timo, Uprimny, Christian, Virgolini, Irene, Kairemo, Kalevi, Joensuu, Timo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer Berlin Heidelberg 2017
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5787223/
https://ncbi.nlm.nih.gov/pubmed/29247284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-017-3895-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi